Celularity and Imugene are collaborating on the novel approach to treatment of solid tumors.
A new research collaboration between Celularity and Imugene will focus on assessing the therapeutic potential of a combination approach to treating solid tumors using CAR T-cell therapy and an oncolytic virus.1
In a joint statement, the clinical-stage biotechnology and immuno-oncology companies disclosed that they will launch nonclinical in vitro and in vivo studies this year to assess the novel combination of Celularity’s CD19-targeting, placental-derived, off-the-shelf allogeneic CAR T cell therapy, CyCART-19, with Imugene’s CF33-CD19, a CD19 oncolytic virus technology.1
The strategy is to utilize the oncolytic virus to prime the tumor cells for destruction by eliciting CD19, which serves as a target for the CAR T-cell therapy.
“We are excited to initiate this research collaboration, which we believe will lay the foundation for a new approach to the treatment of solid tumors,” Robert J. Hariri, MD, PhD, founder, chairperson, and chief executive officer of Celularity, Inc. stated in a press release.1 “Most solid tumors have variable targetable antigens, limiting CAR T-cell therapy efficacy. This treatment strategy with Imugene has the potential to apply to a new range of indications by enabling CD19-targeted cellular medicine to expand from its current effective usage in CD19-positive lymphomas and leukemia and potentially become applicable to a variety of solid tumors through inducing uniform expression of CD19 in solid tumors.”
In May 2021, Imugene Ltd. entered into a licensing agreement with City of Hope for the patents covering the cell therapy technology platform, which includes CF33-CD19, an agent that had been developed at the institution.2
A scientific team led by Saul Priceman, PhD, an assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation, at City of Hope, engineered an oncolytic virus so that it would express a nonsignaling, truncated CD19 protein for tumor-selective delivery, which would enable CD19 targeting by CAR T cells.
Preclinical data published in the journal Scientific Translational Medicine indicated that infecting tumor cells with an oncolytic vaccinia virus that codes for truncated CD19 resulted in the production of de novo CD19 at the cell surface prior to virus-mediated tumor lysis.3 Moreover, cocultured CD19-targeted CAR T cells were found to secrete cytokines and showcase strong cytolytic activity in infected tumors. When OV19t and CD19-targeted CAR T cells were administered to mouse models, disease control was observed.
CyCART-19 is a placental-derived T-cell therapy that was developed with a CAR that is cryopreserved, allogeneic, and designed to be available as an off-the-shelf option.4 The therapy is under investigation as a potential option for patients with B-cell malignancies; it is designed to target the CD19 receptor.
Placental-derived T cells are mostly CD45RA+, readily expand ex vivo, and express markers of stem cell memory, unlike adult peripheral blood mononuclear cell–derived T cells. Moreover, placental-derived T cells are hypothesized to have a lower expression of effector or exhaustion markers, which could translate to a greater potential for proliferation in vivo.
“We believe the synergy between Celularity’s placental-derived cells and our OnCARlytic platform has the potential to shift the cellular medicine paradigm,” Leslie Chong, managing director and chief executive officer of Imugene, stated in a press release. “In preclinical studies, Celularity’s cellular therapies have shown the ability to overcome limitations that have hindered other approaches, including increased proliferation and persistence in vivo, resistance to T-cell exhaustion, and low immunogenicity, which allows for repeated dosing. These unique characteristics perfectly align with our vision for a combination treatment strategy, and we look forward to closely working together to bring this treatment strategy to the clinic and patients in need.”